<DOC>
	<DOCNO>NCT01742533</DOCNO>
	<brief_summary>Premature ovarian failure ( POF ) refers occurrence amenorrhoea , elevate serum gonadotrophin hypoestrogenism level female age 40 . It important physical psychological consequences/impact patient . Premature ovarian failure ( POF ) currently manage non-physiological sex steroid regimens inadequate optimize uterine characteristic . Human umbilical cord mesenchymal stem cell ( hUCMSCs ) human cord blood mononuclear cell ( hCBMNCs ) show ability modulate immune response enhance angiogenesis , suggest novel promising therapeutic strategy POF . In study , safety efficacy hUCMSCs hCBMNCs transplantation combine Hormone Replacement Therapy evaluate patient Premature Ovarian Failure . Participants follow expected average 48 week .</brief_summary>
	<brief_title>Stem Cell Therapy Combined Hormone Replacement Therapy Patients With Premature Ovarian Failure</brief_title>
	<detailed_description />
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Primary Ovarian Insufficiency</mesh_term>
	<mesh_term>Menopause , Premature</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Between age 18 39 year , Female . Diagnosed Premature Ovarian Failure，and currently receive Hormone Replacement Therapy ; Willing sign Informed Consent Form . Fragile X chromosome . polycystic ovary syndrome . HIV+ . Autoimmune disease , e.g . lupus erythematosus , multiple sclerosis . Severe pulmonary hematological disease , malignancy hypoimmunity . Currently undertake treatment may affect safety/efficacy stem cell . Pregnancy lactation Enrollment trial last 3 month . • Other criterion investigator consider improper inclusion .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Hormone Replacement Therapy，</keyword>
	<keyword>Premature Ovarian Failure，</keyword>
	<keyword>Stem Cell Therapy</keyword>
</DOC>